This article is more than 5 years old. Information may no longer be current.
Clinical trials accumulate data for novel anti-VEGF
Click Here to Manage Email Alerts
CHICAGO — A new anti-VEGF indicated for use in wet age-related macular degeneration achieved clinically meaningful and durable vision improvement in several studies with reduced dosing, according to a speaker here.
Conbercept, a fusion protein produced in a manner similar to Elyea (aflibercept, Regeneron) is approved for use in China, and discussions are underway to bring this drug to the U.S. and other countries, Peter K. Kaiser, MD, told colleagues at the Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
Peter K. Kaiser
“This drug actually lasts slightly longer — about a week or so is the half-life in vitreous. There’s a longer activity time than in other fusion proteins,” Kaiser said.
Results of the HOPE, AURORA, BRIDGE and PHOENIX clinical trials conducted in China led to the approval of conbercept there.
“It appears to have a durable visual acuity and meaningful visual acuity result and hopefully will offer us something more outside the country of China,” Kaiser said.
Disclosure: Kaiser has relevant financial relationships with Alcon, Bayer, Genentech, Chengdu Kanghong Biotech, Novartis, Ohr Pharmaceuticals, Ophthotech and Regeneron.